Retatrutide vs Tirzepatide: Is Triple Agonism Worth the Wait?
Comparing retatrutide (triple GLP-1/GIP/glucagon agonist, Phase 3) vs tirzepatide (approved dual GLP-1/GIP agonist): efficacy data, mechanisms, and what the next-generation compound offers.
Retatrutide
LY3437943
Clinical TrialsTirzepatide
Mounjaro
FDA ApprovedRetatrutide
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
Tirzepatide
A dual GLP-1 and GIP receptor agonist representing the next generation of metabolic peptides. Achieves greater weight loss than semaglutide with average reductions of 20-22.5% body weight.
Common Questions
Q: Is retatrutide better than tirzepatide?
See the full comparison in our detailed guide.
Q: What does glucagon agonism add?
See the full comparison in our detailed guide.
Q: When will retatrutide be approved?
See the full comparison in our detailed guide.
Q: How much more weight loss does retatrutide produce?
See the full comparison in our detailed guide.
Q: What are the side effects of retatrutide?
See the full comparison in our detailed guide.
Our Verdict
Winner: Retatrutide (data-based); Tirzepatide (available now)
Phase 3 data for retatrutide shows ~24% body weight reduction — exceeding tirzepatide's 20-22%. The addition of glucagon receptor agonism increases energy expenditure (thermogenesis), pushing efficacy further. However, retatrutide is not yet approved. For immediate access, tirzepatide remains the most effective available option.